Introduction
Human hepatocyte growth factor (hHGF), initially identified and cloned as a potent mitogen for hepatocytes, was shown to have mitogenic, antiapoptotic, angiogenic, and antifibrotic effects in multiple cell types, especially epithelial and endothelial cells [1] [2] [3] [4] . Recent research has shown that hHGF can attenuate brain, heart and kidney ischemia/ reperfusion (I/R) injury [5] [6] [7] . However, the half-life of hHGF is very short, and hHGF that enters the body is metabolized and rapidly cleared from tissues [8] . In addition, the biological activities of hHGF cannot be anticipated when the protein is injected in solution form because of its rapid excretion from the injection site by diffusion [9] . Thus, one possible method for enhancing the in vivo activity of hHGF is to control the release of hHGF over a prolonged time period by incorporating it into a copolymer nanocarrier.
In our previous study, we reported PEG-b-P(ELG-g-PLL) as a potential protein nanocarrier to prolong the in vivo half-life of a protein [10] . In the present study, because the isoelectric point (pI) of hHGF was 5.5, hHGF combined with PEG-b-P(ELG-g-PLL) copolymer through electrostatic interactions at pH 7.4. The encapsulated hHGF demonstrated sustained release, which facilitated the investigation of the protective action of hHGF. Thus, hHGF-loading capacity and in vitro release were measured. Via in vivo research, we sought to evaluate the sustained pharmacological function of hHGF/PEG-b-P(ELG-g-PLL) for protecting different organs against I/R injury in rats, using free hHGF as a control.
Materials and Methods

Materials
Sprague-Dawley (SD) rats (160-200 g) were purchased by Jiaxing University Medical College, Jiaxing, China. All reagents and drugs were supplied from Sigma.
Synthesis and cytotoxicity of block copolymer PEG -b-P(ELG -g-PLL)
Detailed methods for synthesizing and analyzing the cytotoxicity of the block copolymer PEG-b-P(ELGg-PLL) are provided in our prior work [10] .
Cytotoxicity of the block copolymer PEG-b-P(ELG-g-PLL)
As described in our previous article [10] , EC9706 cells were cultured in a 96-well plate with 5×10 3 cells per well and incubated for 24 h. The original medium was removed, and MTT solution was added to each well. During incubation, MTT levels decreased in viable cells, leading to the precipitation of insoluble formazan crystals. The minimal essential medium was removed, and ethanol-dimethyl sulfoxide solution was added to each well. After the dark blue crystals of MTT formazan were completely solubilized (15-20 min) , the absorbance of each well was measured at 570 nm using a multimode reader. A well without cells that was incubated with the MTT solution was used as the blank reference. PEG-b-P(ELG-g-PLL) was used as a positive cytotoxicity control. Cells cultivated in a well were used as a negative cytotoxicity control. Values were expressed as optical densities (ODs). The obtained absorbance values were subtracted from the absorbance of the ethanol-dimethyl sulfoxide blank and presented as percentages relative to the control, as detailed in equation 1:
(%) Cell viability=(OD sample -OD blank )/(OD cells -OD blank )×100 (1)
Encapsulation and in vitro release of hHGF in PEG-b-P(ELG-g-PLL)
Detailed methods can be found in our previous work [10] .
Blood hHGF concentration evaluation A total of 30 SD rats were administered a dose of 1 mg/kg hHGF or hHGF/PEG-b-P(ELG -g-PLL) by abdominal subcutaneous injection. Blood (0.2 mL) was extracted and transferred into heparinized tubes at specified time intervals. The blood was immediately separated by centrifugation (10000 × g for 20 min at 4°C) and stored at -80°C for the following analyses. The concentration of hHGF and hHGF/PEG b-P(ELG-g-PLL) in rat blood was measured by enzyme-linked immunosorbent assay (ELISA) following previous methods [11] .
Statistical analysis
All data are expressed as the mean values ± the standard deviation (SD). An analysis of variance (ANOVA) and Student's t test were used to evaluate statistical significance. A value of less than 0.01 (P<0.01) was used to establish statistical significance.
Results
Synthesis and characterization of PEG-b-P(ELG-g-PLL)
The PEG-b-P(ELG-g-PLL) consisted of a linear PEG block and a brush-like PLL block ( Figure 1 ). In our study, the molecular weight of the PEG block was 5000 Da, and the polymerization degree of the PELG brush backbone was 50; in addition, the polymerization degrees of the PLL brush side chains were 3 and 6. The synthesis was performed in a fourstep procedure as shown in Figure 1 . The 1 H-nuclear magnetic resonance (NMR) spectra of PEG-b-P(ELG-g-PLL) are shown in Figure 2A . The gel permeation chromatograms (GPCs) of PEG-b-P(ELG-g-PLL) are shown in Figure 2B . M n (kDa)/ 1 H NMR and M n (kDa)/GPC refer to our previous work [10] .
Cell viability
The cytotoxicities of PEG-b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 6 ) on EC9706 cells were measured within 24 h of culturing, and the results are shown in Figure 3 . The block copolymer showed high cell viability even under concentrations as high as 500 mg/L. Cell viabilities were (100±1.34)% and (100±1.11)% in 0 mg/L of PEG-b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 6 ), respectively; (95±1.78)% and (93±1.26)% in 10 mg/L of PEG- 
PEG-b-P(ELG 50 -g-PLL 6 ), respectively; and (85±2.01)% and (81±1.17)% in 500 mg/L of PEGb-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 6 ), respectively.
Loading capacity of hHGF in PEG-b-P(ELG-g-PLL)
hHGF could be efficiently entrapped by PEG-b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 6 ) under physiological pH via the electrostatic interactions between the positively charged PLL and the negatively charged hHGF. The loading capacity of hHGF was determined to be 8.21% in PEG-b-P(ELG 50 -g-PLL 3 ), and the loading capacity of hHGF was determined to be 9.78% in PEG-b-P(ELG 50 -g-PLL 6 ) ( Table 1) .
Characterization of the hHGF/PEG-b-P(ELG-g-PLL) complex
The hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) complexes were observed using transmis sion electron microscopy (TEM), and a representative image is shown in Figure 4A . The hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) complexes also adopted a spherical structure, and the diameters were approximately 51 and 67 nm, respectively ( Table 1) . The hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) complexes were further character ized with a granulometer. The average particle size distribu tions of PEG-b-P(ELG 50 -g-PLL 3 ), PEG-b-P(ELG 50 -g-PLL 6 ) and hHGF-loaded b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 6 ), respectively; (93±2.32)% and (91±1.34)% in 50 mg/L of PEG-b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 6 ), respectively; (92±2.56)% and (90±2.22)% in 100 mg/L of PEG-b-P(ELG 50 -g-PLL 3 ) and PEGb-P(ELG 50 -g-PLL 6 ), respectively; (90±3.01)% and (88±1.56)% in 125 mg/L of PEG-b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 6 ), respectively; (89±0.89)% and (87±1.13)% in 200 mg/L of PEG-b-P(ELG 50 -g-PLL 3 ) and PEGb-P(ELG 50 -g-PLL 6 ), respectively; (87±1.11)% and (85±1.44)% in 300 mg/L of PEG-b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 6 ), respectively; (86±1.34)% and (83±2.45)% in 400 mg/L of PEG-b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 6 ) are shown in Figure 4B and Table 1 . The average diameters of PEG-b-P(ELG 50 -g-PLL 3 ), PEG-b-P(ELG 50 -g-PLL 6 ), hHGF/PEG-b-P(ELG 50 -g-PLL 3 ), and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) were approximately 6, 10, 16, and 21 nm, respectively.
In vitro release of hHGF from PEG-b-P(ELG-g-PLL)
The release of hHGF from PEG-b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 6 ) was measured via dialysis (MWCO, 100 kDa) at 37°C with 5 mL of hHGF-loaded PEG-b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 -g-PLL 6 ) against a 0.02 mol/L phosphate buffer (PB) solution (pH 7.4). The cumula tive release profile of PEG-b-P(ELG 50 -g-PLL 3 ) and PEG-b-P(ELG 50 - Table 1 . Particle size, TEM, and hHGF-loading capacity of PEG-b-P(ELG-g-PLL). Abbreviations: TEM, transmission electron microscopy; PEG-b-P(ELG-g-PLL), poly(ethylene glycol)-b-(poly(ethylenediamine l-glutamate)-g-poly(l-lysine)); NA, not applicable g-PLL 6 )-encapsulated hHGF is shown in Figure 5 . After 2 h, approximately 28.94% and 19.83% of the hHGF was released from hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ), respectively, which is indicative of an initial burst release of hHGF. Approximately 69.16% and 57.51% of the hHGF was released after 7 days, which is indicative of biphase release profiles from hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ).
Serum hHGF concentration evaluation
As shown in Figure 6 , the concentration of hHGF in the plasma of SD rats following a single subcutaneous injection in the hHGF group at a dose of 1 mg/kg rapidly reached a C max of 534 ng/mL at a T max of 40 min and then declined to baseline values within 3 h of administration. The plasma hHGF concentration in SD rats following a single subcutaneous injection in the hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) group at a dose of 1 mg/kg reached a C max of 74.65 ng/mL at a T max of 3 h and then declined to baseline values within 7 d of administration. The plasma hHGF concentration in SD rats following a single subcutaneous injection in the hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) group at a dose of 1 mg/kg reached C max of 65.34 ng/mL at a T max of 6 h and then declined to baseline values within 3 d of administration. These results showed that the release of hHGF from hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) was sustained in comparison to the results obtained in the hHGF group.
Evaluation of injury to different organs
As shown in Figure 7 , the injuries to the brain, heart and kidney in the I/R groups were higher than those in the Sham group, as assessed via high-speed camera imaging. The injuries to the brain, heart and kidney in the hHGF, hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) groups were less than those in the I/R group, as assessed via high-speed camera imaging. In particular, the hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) group showed significantly less injury than the I/R group based on high-speed camera imaging.
Brain water content, SOD activity and MDA level following brain I/R injury
As shown in Figure 8 , the brain water content in the I/R group was higher than that in the Sham group (P<0.01). The brain water content in the Sham group reached 18.17±3.18%, whereas the brain water content in the I/R group reached 75.29±5.05%. Administration of hHGF reduced the brain water content to 62.17±2.89% (P<0.01). In addition, administration of hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) also reduced the brain water content to 43.27±3.01% and 50.08±4.05%, respectively, while hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) significantly reduced the brain water content (P<0.01) ( Figure 8A ). The SOD activity in the I/R group was less than that in the Sham group (P<0.01). The SOD activity in the Sham group reached 154.25±21.17 U/mg; however, the SOD activity in the I/R group reached 72.31±15.39 U/mg. Administration of hHGF increased the SOD activity to 93.85±19.41 U/ mg (P<0.01). In addition, administration of hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) also increased the SOD activity to 131.18±23.28 U/mg and 112.08±18.85 U/ mg, respectively, while hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) significantly increased the SOD activity (P<0.01) ( Figure 8B ). The MDA level in the I/R group was higher than that in the Sham group (P<0.01). The MDA level in the Sham group reached 3.15±1.89 μmol/g, while the MDA level in the I/R group reached 12.05±2.01 μmol/g. Administration of hHGF increased the MDA level to 8.87±2.25 μmol/g (P<0.01). In addition, administration of hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) also increased the MDA level to 6.18±1.54 μmol/g and 7.74±2.18 μmol/g, respectively, while hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) significantly decreased the MDA level (P<0.01) ( Figure 8C ).
BUN level, Scr level, SOD activity and MDA level following renal I/R injury
As shown in Figure 8 , the BUN level in the I/R group was higher than that in the Sham group (P<0.01). The BUN level in the Sham group reached 5.04±1.89 mmol/L, while the BUN level in the I/R group reached 24.52±2.38 mmol/L. Administration of hHGF reduced the BUN level to 16.34±3.05 mmol/L (P<0.01). In addition, administration of hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) also reduced the BUN level to 12.16±2.45 mmol/L and 14.36±3.14 mmol/L, respectively, while hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) significantly reduced the BUN level (P<0.01) ( Figure 8D ). The Scr level in the I/R group was higher than that in the Sham group (P<0.01). The Scr level in the Sham group reached 7.32±2.16 μmol/L, whereas the Scr level in the I/R group reached 26.16±3.28 μmol/L. Administration of hHGF reduced the Scr level to 19.05±1.89 μmol/L (P<0.01). In addition, administration of hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) also reduced the Scr level to 15.32±3.06 μmol/L and 17.23±3.18 μmol/L, respectively, while hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) significantly reduced the Scr level (P<0.01) ( Figure 8E ). The SOD activity in the I/R group was less than that in the Sham group (P<0.01). The SOD activity in the Sham group reached 121.5±2.08 U/mg, while the SOD activity in the I/R group reached 51.17±1.75 U/ mg. Administration of hHGF increased the SOD activity to 78.31±2.17 U/mg (P<0.01). In addition, administration of hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) also increased the SOD activity to 108.3±3.01 U/mg and 89.15±2.14 U/mg, respectively, while hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) significantly increased the SOD activity (P<0.01) ( Figure 8F ). The MDA level in the I/R group was higher than that in the Sham group (P<0.01). The MDA level in the Sham group reached 23.4±3.2 nmol/mg, while the MDA level in the I/R group reached 70.5±5.6 nmol/mg. Administration of hHGF increased the MDA level to 58.8±6.3 nmol/mg (P<0.01). In addition, administration of hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/ PEG-b-P(ELG 50 -g-PLL 6 ) also increased the MDA level to 42.9±2.8 nmol/mg and 50.3±4.1 nmol/mg, respectively, while hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) significantly decreased the MDA level (P<0.01) ( Figure 8G ). red with that of the brain I/R injury group. The damage to the heart in the heart I/R injury group was greater than that in the Sham group. Administration of hHGF decreased the heart damage compared with that of the heart I/R injury group. Administration of hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) significantly decreased the heart damage compared with that of the heart I/R injury group. Administration of hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) further significantly decreased the heart damage compared with that of the heart I/R injury group. The kidney damage in the kidney I/R injury group was greater than that in the Sham group. Administration of hHGF decreased the kidney damage compared with that of the kidney I/R injury group. Administration of hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) significantly decreased the kidney damage compared with that of the kidney I/R injury group. Administration of hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) further significantly decreased the kidney damage compared with that of the kidney I/R injury group.
abdominal subcutaneous injection of hHGF alone had a limited effect on I/R injury due to the short half-life of hHGF. Specifically, we observed that high numbers of hHGF injections (hHGF was administered once per day by abdominal subcutaneous injection starting 7 days prior to the I/R procedure) could reduce I/R injury in the hHGF group; however, a single abdominal subcutaneous injection of hHGF-loaded PEG-b-P(ELG-g-PLL) 7 days prior to the I/R procedure remarkably resulted in reduced I/R injury relative to hHGF alone and decreased injection times. These findings indicated that the use of PEG-b-P(ELG-g-PLL) is warranted for hHGF therapy for I/R injury and improved the half-time of hHGF. Drugs were administered 7 days prior to I/R induction given the in vitro release and hHGF plasma concentration results presented in Figures 5 and 6 .
The potential for PEG-b-P(ELG-g-PLL) to be used as a protein nanocarrier was previously reported by our group [10] . The block copolymer was composed of a linear PEG block and a brush-like PLL block. At pH 7.4, the positively charged PLL brush block and the negatively charged hHGF (pI=5.5) combined to form a polyion complex through electrostatic interac tions. The encapsulated hHGF showed sustained release, which facilitated further investigation into the protective effect of hHGF. Thus, our study measured the hHGF-loading capacity and in vitro release of these complexes. With respect to in vitro release, we found that hHGF release from both hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) and hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) could be sustained for 7 days but that hHGF release from hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) was significantly greater than hHGF release from hHGF/PEG-b-P(ELG 50 -g-PLL 6 ). However, hHGFloading capacity was lower for PEG-b-P(ELG 50 -g-PLL 3 ) than for PEG-b-P(ELG 50 -g-PLL 6 ). A possible reason for these phenomena is that at pH 7.4, the high amino density of PEG-b-P(ELG 50 -g-PLL 6 ) led to strong positive charges that strengthened the connection between hHGF and PEG-b-P(ELG 50 -g-PLL 6 ) by fostering strong electrostatic interactions, thereby improving hHGF-loading capacity but increasing the difficulty of hHGF release from hHGF/ PEG-b-P(ELG 50 -g-PLL 6 ). In in vivo research, we found that blood concentrations of hHGF could be sustained for 7 days in the hHGF/PEG-b-P(ELG 50 -g-PLL 3 ) group and 3 days in the hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) group. There were contradictions between the in vivo and in vitro findings; these contradictions may be attributable to the complex environment and the high amino density of PEG-b-P(ELG 50 -g-PLL 6 ), which caused hHGF to be difficult to release from hHGF/PEG-b-P(ELG 50 -g-PLL 6 ) in vivo. In addition, this was the first study to show that hHGF and hHGF/PEG-b-P(ELG-g-PLL) were both capable of attenuating I/R injury (brain, heart and kidney).
Previous studies have demonstrated that I/R injury is a major concern in brain, heart and kidney surgeries and an important pathophysiological phenomenon in clinical medicine [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Although the pathogenesis of I/R damage has not been well characterized, pretreatment with drugs or transient ischemia prior to I/R can reduce tissue injury; however, ischemic preconditioning is difficult to perform in clinical practice. Therefore, it is necessary to search for and study drugs that can effectively prevent and cure I/R injury. The gradual transition from animal experiment to clinical application has been a major task for basic and clinical workers. Currently, many drugs have been shown to experimentally modify pathophysiological conditions [30] [31] [32] . hHGF, also known as scatter factor, has been isolated and purified from rat platelets [33] . However, in many investigations, hHGF decreased brain I/R injury via an ERK-dependent pathway, reduced heart I/R injury via the regulation of cell apoptosis and alleviated kidney I/R injury via the inhibition of apoptotic cell death [5] [6] [7] . In this study, we found that in rats, both hHGF and hHGF/PEG-b-P(ELG-g-PLL) protected the brain and kidney against I/R injury by decreasing oxidative stress damage and protected the heart against I/R injury by reducing CK and LDH release. In particular, I/R injury was markedly decreased in hHGF/PEG-b-P(ELG-g-PLL)-treated rats compared with control rats.
Conclusion
the present study showed that hHGF and hHGF/PEG-b-P(ELG-g-PLL) both prevented brain, heart and kidney damage after I/R injury in an animal model. Indeed, hHGF may play an important role in clinical situations associated with brain, heart and kidney dysfunction after I/R injury. More importantly, the hHGF nanocarrier PEG-b-P(ELG-g-PLL) may significantly improve hHGF bioactivity and protect against I/R injury.
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